Metropolis Healthcare stock had jumped 17% in early trades after a leading brokerage house had upgraded the stock from 'sell' to 'add'. The stock currently trades at 27 times forward EPS of 2022. Metropolis Healthcare is expected to grow at 11-12% revenue over the next 10 years. The highly profitable B2C business now accounts for 44% of revenues in and B2C revenues are expected to grow at 19%. The immediate risk for the company is the lockdown which could impact the company with nearly 60% of its cost structure as fixed costs. However, with the government permitting testing for COVID 19 in private labs, that opens a huge window opportunity for Metropolis.